nach oben

Erschienen in:

21.01.2019 | Stem Cell Transplantation (R Maziarz, Section Editor)

Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

verfasst von: Stacie Ittershagen, Solveig Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, Manisha Patel, Tetiana Taran, Oezlem Anak, Charlene Hall, Mimi Leung, Deborah Roccoberton, Florence Salmon, Miriam Fuchs, Vadim Romanov, David Lebwohl

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children’s Hospital of Philadelphia, and Novartis to commercialize the chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel (CTL019; Kymriah®; Novartis Pharma AG, Basel, Switzerland).

Recent Findings

Tisagenlecleucel was the first CAR-T therapy and the first gene therapy to receive US Food and Drug Administration approval in 2017, with an initial indication for pediatric and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia, followed by approval in May 2018 for a second indication in adult patients with r/r diffuse large B cell lymphoma. Subsequent approvals in the European Union, Switzerland, and Canada soon followed.

Summary

The tisagenlecleucel success story represents the development and commercialization of a first-of-its-kind personalized cellular therapy with a manufacturing process that supports commercial production and ongoing global clinical trials in a growing number of countries.

Nur mit Berechtigung zugänglich

Kymriah (tisagenlecleucel) suspension for intravenous infusion [package insert]. East Hanover, NJ: Novartis Pharmceuticals Corporation; 2018.

Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33. https://doi.org/10.1056/NEJMoa1103849.CrossRefPubMedPubMedCentral

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. https://doi.org/10.1126/scitranslmed.3002842.CrossRefPubMedPubMedCentral

June CH. Chimeric antigen receptors: engineering designer T cells for cancer therapy. Presented at: 2012 American Society of Clinical Oncology annual meeting, June 5, 2012; Chicago, IL. Available at: https://meetinglibrary.asco.org/record/68679/video. Accessed November 7, 2018.

Penn Medicine. University of Pennsylvania and Novartis form Alliance to expand use of personalized T cell therapy for Cancer patients [press release]. Available at: https://www.pennmedicine.org/news/news-releases/2012/august/university-of-pennsylvania-and. Accessed November 7, 2018. Philadelphia, PA: Penn Medicine; 2012.

Penn Medicine. Novartis-Penn Center for advanced cellular therapeutics unveiled at Penn medicine [press release]. Available at: https://www.pennmedicine.org/news/news-releases/2016/february/novartispenn-center-for-advanc. Accessed November 7, 2018. Philadelphia, PA: Penn Medicine; 2016.

United States Adopted Names Council. Tisagenleceleucel (BC-84). Statement on a nonproprietary name adopted by the USAN council. March 29, 2017. Available at: https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ftisagenlecleucel.pdf. Accessed November 7, 2018.

Lebwohl D. KYMRIAH (tisagenlecleucel) case study: CD-19-directed genetically modified autologous T-cell immunotherapy for pediatric acute lymphoblastic leukemia (ALL). Presented at: Accelerating Anticancer Agent Development Validation Workshop; May 2-4, 2018.

Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101. https://doi.org/10.1016/j.omtm.2016.12.006.CrossRefPubMed

10.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448–58. https://doi.org/10.1158/1078-0432.CCR-11-0485.CrossRefPubMed

11.

Clinicaltrials.gov. Pilot study of redirected autologous T-cells engineered to contain anti-CD19 attached to TCR and 4-1BB signaling domains in patient with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. NCT01029366. Available at: https://clinicaltrials.gov/ct2/show/NCT01029366. Accessed November 7, 2018.

12.

Clinicaltrials.gov. Pilot study of donor lymphocyte infusions using donor T cells engineered to contain anti-CD19 attached to TCR And 4-1BB signaling domains in patients with relapsed CD19+ ALL after allogeneic stem cell transplantation. NCT01551043. Available at: https://clinicaltrials.gov/ct2/show/NCT01551043. Accessed November 7, 2018.

13.

Clinicaltrials.gov. CHP 959 - A phase I/IIA study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRzeta and 4-1BB signaling domains in patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. NCT01626495. Available at: https://clinicaltrials.gov/ct2/show/NCT01626495. Accessed November 7, 2018.

14.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222.CrossRefPubMedPubMedCentral

15.

Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia. NCT02228096. Available at: https://clinicaltrials.gov/ct2/show/NCT02228096. Accessed November 7, 2018.

16.

Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia. NCT02435849. Available at: https://clinicaltrials.gov/ct2/show/NCT02435849. Accessed November 7, 2018.

17.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54. https://doi.org/10.1056/NEJMoa1708566.CrossRefPubMedPubMedCentral

18.

Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NCT02445248. Available at: https://clinicaltrials.gov/ct2/show/NCT02445248. Accessed November 7, 2018.

19.

•• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. https://doi.org/10.1056/NEJMoa1709866 Publication of the ELIANA clinical trial, which led to regulatory approval of tisagenlecleucel for pediatric and young adult patients with acute lymphoblastic leukemia.CrossRefPubMedPubMedCentral

20.

•• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018 [in press]. Publication of the JULIET clinical trial, which led to regulatory approval of tisagenlecleucel for adult patients with diffuse large B-cell lymphoma.

21.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. https://doi.org/10.1056/NEJMoa1215134.CrossRefPubMedPubMedCentral

22.

Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–40. https://doi.org/10.1016/j.cell.2017.01.016.CrossRefPubMedPubMedCentral

23.

Novartis Pharmaceuticals Corporation. Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL [press release]. Available at: https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda. Accessed November 7, 2018. East Hanover, NJ: Novartis Pharmaceuticals Corporation.

24.

Bach PB. National coverage analysis of CAR-T therapies - policy, evidence, and payment. N Engl J Med. 2018;379(15):1396–8. https://doi.org/10.1056/NEJMp1807382.CrossRefPubMed

25.

Hao Y, Eldjerou L, Yang H, Qi CZ, Globe D. Cost-effectiveness analysis of Kymriah™ for the treatment of pediatric and young adult patients with relapsed or refractory B-Cell acute lymphoblastic leukemia in the United States. Presented at: American Society of Hematology Annual Meeting; December 9–12, 2017; Atlanta, GA. Abstract 609.

26.

Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141. https://doi.org/10.1186/s13045-018-0681-6.CrossRefPubMedPubMedCentral

27.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8. https://doi.org/10.1038/nm.4441.CrossRefPubMed

28.

Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics. 2018;11:127–37. https://doi.org/10.1016/j.omto.2018.10.006.CrossRefPubMedPubMedCentral

29.

Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW. Engineering Axl specific CAR and SynNotch receptor for cancer therapy. Sci Rep. 2018;8(1):3846. https://doi.org/10.1038/s41598-018-22252-6.CrossRefPubMedPubMedCentral

30.

Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–97. https://doi.org/10.15252/emmm.201607485.CrossRefPubMedPubMedCentral

31.

Yeku OO, Purdon T, Spriggs DR, Brentjens RJ. Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer. J Clin Oncol. 2018;36(5_suppl):12. https://doi.org/10.1200/JCO.2018.36.5_suppl.12.CrossRef

32.

Majors BS, Spencer T, Ericson SG, Romanov V. Initial experience in US commercial manufacturing of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy for pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Presented at: 23rd European Hematology Association Meeting; June 14–17, 2018; Stockholm, Sweden. Abstract PS1156.

Titel: Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
verfasst von: Stacie Ittershagen
Solveig Ericson
Lamis Eldjerou
Ali Shojaee
Eric Bleickardt
Manisha Patel
Tetiana Taran
Oezlem Anak
Charlene Hall
Mimi Leung
Deborah Roccoberton
Florence Salmon
Miriam Fuchs
Vadim Romanov
David Lebwohl
Publikationsdatum: 21.01.2019
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 1/2019
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-019-0498-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Treatment-Free Remission in CML: the US Perspective

Correction to: Strategies for Predicting Response to Checkpoint Inhibitors

The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders

Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?

Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie